<p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - 獲取免費報告) 的股價在週四交易前出現跳漲。該股票此前收於 50.00 美元，但開盤價為 53.33 美元。Soleno Therapeutics 的股票最後交易價格為 49.7560 美元，成交量為 859,773 股。</p>
<p>獲取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>一些研究分析師最近對 SLNO 股票發表了評論。Wall Street Zen 在 11 月 8 日的報告中將 Soleno Therapeutics 的評級從 “持有” 上調至 “買入”。高盛集團在 10 月 7 日的研究報告中對 Soleno Therapeutics 的股票設定了 125.00 美元的目標價，並給予該股票 “買入” 評級。HC Wainwright 在 8 月 18 日的報告中重申了 “買入” 評級，並將 Soleno Therapeutics 的目標價從 100.00 美元上調至 110.00 美元。富國銀行在 11 月 5 日的報告中重申了 “增持” 評級，並將 Soleno Therapeutics 的目標價從 123.00 美元下調至 106.00 美元。最後，Lifesci Capital 在 9 月 10 日的報告中將 Soleno Therapeutics 的股票評級上調至 “強力買入”。兩位分析師給予該股票 “強力買入” 評級，十二位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Soleno Therapeutics 目前的平均評級為 “買入”，共識目標價為 111.46 美元。</p>
<p><strong>查看我們對 Soleno Therapeutics 的最新分析</strong></p>
<h2>Soleno Therapeutics 股票表現</h2>
<p>該公司的 50 日簡單移動平均線為 56.34 美元，200 日簡單移動平均線為 68.73 美元。公司的流動比率為 16.08，速動比率為 15.88，債務與股本比率為 0.10。該股票的市值為 26.6 億美元，市盈率為-26.90，貝塔值為-3.15。</p>
<p>Soleno Therapeutics (NASDAQ:SLNO - 獲取免費報告) 最近在 11 月 4 日發佈了其財報。公司報告本季度每股收益為 0.47 美元，超出分析師一致預期的 0.08 美元，超出幅度為 0.39 美元。該公司本季度的收入為 6602 萬美元，而分析師預期為 4746 萬美元。整體來看，賣方分析師預計 Soleno Therapeutics, Inc.在本年度將發佈-3.72 美元的每股收益。</p>
<h2>Soleno Therapeutics 的機構交易</h2>
<p>機構投資者最近對該公司的持倉進行了調整。Wellington Management Group LLP 在第三季度將其在 Soleno Therapeutics 的持股增加了 272.3%。Wellington Management Group LLP 目前擁有 2312095 股該公司的股票，價值 156298000 美元，此前在上個季度又購買了 1691057 股。Adage Capital Partners GP L.L.C.在第一季度將其在 Soleno Therapeutics 的持股增加了 58.2%。Adage Capital Partners GP L.L.C.目前擁有 4392696 股該公司的股票，價值 313858000 美元，此前在上個季度又收購了 1616720 股。Braidwell LP 在第三季度獲得了 Soleno Therapeutics 的新頭寸，價值約為 86662000 美元。Invesco Ltd.在第三季度將其在 Soleno Therapeutics 的持股增加了 132.3%。Invesco Ltd.目前擁有 1500525 股該公司的股票，價值 101435000 美元，此前在上個季度又購買了 854551 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在 Soleno Therapeutics 的持股增加了 47.2%。Price T Rowe Associates Inc. MD 目前擁有 2400418 股該公司的股票，價值 171510000 美元，此前在上個季度又購買了 769700 股。97.42% 的股票目前由機構投資者和對沖基金持有。</p>
<h2>關於 Soleno Therapeutics</h2>
<p>(獲取免費報告)</p>
<p>Soleno Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物是氟氯噻噸氯化物緩釋片，這是一種每日一次的口服藥物，目前正在進行治療普拉德 - 威利綜合症的第三階段臨牀試驗。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Soleno Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>三隻冬季股票具有良好的增長機會</li>
<li>三隻國防股票將受益於軍事支出增加</li>
<li>2026 年反彈股票：三隻標普滯後股有望突破</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>特斯拉多頭看到 500 美元的前景——但空頭警告痛苦的反轉</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Soleno Therapeutics 嗎？</h2>
<p>在考慮 Soleno Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Soleno Therapeutics 並不在名單上。</p>
<p>雖然 Soleno Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Soleno治療

<p>Soleno Therapeutics（納斯達克代碼：SLNO）股票跳空高開，開盤價為 53.33 美元，前一交易日收盤價為 50.00 美元，最後交易價為 49.7560 美元。分析師對該股票給予了一致的 “買入” 評級，目標價為 111.46 美元。公司報告了強勁的財報，盈利每股 0.47 美元，收入為 6602 萬美元，均超出預期。機構投資者顯著增加了對公司的持股。Soleno Therapeutics 專注於開發罕見疾病的治療方案，其主要候選藥物正在進行針對普拉德 - 威利綜合症的第三階段臨牀試驗</p>

<p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report)'s stock price gapped up prior to trading on Thursday . The stock had previously closed at $50.00, but opened at $53.33. Soleno Therapeutics shares last traded at $49.7560, with a volume of 859,773 shares.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc. (NASDAQ:SLNO - 獲取免費報告) 的股價在週四交易前出現跳漲。該股票此前收於 50.00 美元，但開盤價為 53.33 美元。Soleno Therapeutics 的股票最後交易價格為 49.7560 美元，成交量為 859,773 股。</p>
</div><p>Get <strong>Soleno Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Soleno Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research analysts have recently commented on SLNO shares. Wall Street Zen raised Soleno Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 8th. The Goldman Sachs Group set a $125.00 price objective on shares of Soleno Therapeutics and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, October 7th. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $110.00 price objective (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating and issued a $106.00 target price (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a &#34;strong-buy&#34; rating in a report on Wednesday, September 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Soleno Therapeutics presently has an average rating of &#34;Buy&#34; and a consensus price target of $111.46.</p>
<div class="lb-trans"><p>一些研究分析師最近對 SLNO 股票發表了評論。Wall Street Zen 在 11 月 8 日的報告中將 Soleno Therapeutics 的評級從 “持有” 上調至 “買入”。高盛集團在 10 月 7 日的研究報告中對 Soleno Therapeutics 的股票設定了 125.00 美元的目標價，並給予該股票 “買入” 評級。HC Wainwright 在 8 月 18 日的報告中重申了 “買入” 評級，並將 Soleno Therapeutics 的目標價從 100.00 美元上調至 110.00 美元。富國銀行在 11 月 5 日的報告中重申了 “增持” 評級，並將 Soleno Therapeutics 的目標價從 123.00 美元下調至 106.00 美元。最後，Lifesci Capital 在 9 月 10 日的報告中將 Soleno Therapeutics 的股票評級上調至 “強力買入”。兩位分析師給予該股票 “強力買入” 評級，十二位分析師給予 “買入” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat 的數據，Soleno Therapeutics 目前的平均評級為 “買入”，共識目標價為 111.46 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on Soleno Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Soleno Therapeutics 的最新分析</strong></p>
</div><h2>Soleno Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 股票表現</h2>
</div><p>The firm has a fifty day simple moving average of $56.34 and a 200 day simple moving average of $68.73. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -26.90 and a beta of -3.15.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 56.34 美元，200 日簡單移動平均線為 68.73 美元。公司的流動比率為 16.08，速動比率為 15.88，債務與股本比率為 0.10。該股票的市值為 26.6 億美元，市盈率為-26.90，貝塔值為-3.15。</p>
</div><p>Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to analyst estimates of $47.46 million. As a group, sell-side analysts expect that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Soleno Therapeutics (NASDAQ:SLNO - 獲取免費報告) 最近在 11 月 4 日發佈了其財報。公司報告本季度每股收益為 0.47 美元，超出分析師一致預期的 0.08 美元，超出幅度為 0.39 美元。該公司本季度的收入為 6602 萬美元，而分析師預期為 4746 萬美元。整體來看，賣方分析師預計 Soleno Therapeutics, Inc.在本年度將發佈-3.72 美元的每股收益。</p>
</div><h2>Institutional Trading of Soleno Therapeutics</h2>
<div class="lb-trans"><h2>Soleno Therapeutics 的機構交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its holdings in shares of Soleno Therapeutics by 272.3% in the third quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company's stock valued at $156,298,000 after buying an additional 1,691,057 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Soleno Therapeutics by 58.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 4,392,696 shares of the company's stock worth $313,858,000 after acquiring an additional 1,616,720 shares during the last quarter. Braidwell LP acquired a new position in shares of Soleno Therapeutics during the third quarter worth approximately $86,662,000. Invesco Ltd. grew its stake in shares of Soleno Therapeutics by 132.3% during the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company's stock valued at $101,435,000 after purchasing an additional 854,551 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Soleno Therapeutics by 47.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,400,418 shares of the company's stock valued at $171,510,000 after purchasing an additional 769,700 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。Wellington Management Group LLP 在第三季度將其在 Soleno Therapeutics 的持股增加了 272.3%。Wellington Management Group LLP 目前擁有 2312095 股該公司的股票，價值 156298000 美元，此前在上個季度又購買了 1691057 股。Adage Capital Partners GP L.L.C.在第一季度將其在 Soleno Therapeutics 的持股增加了 58.2%。Adage Capital Partners GP L.L.C.目前擁有 4392696 股該公司的股票，價值 313858000 美元，此前在上個季度又收購了 1616720 股。Braidwell LP 在第三季度獲得了 Soleno Therapeutics 的新頭寸，價值約為 86662000 美元。Invesco Ltd.在第三季度將其在 Soleno Therapeutics 的持股增加了 132.3%。Invesco Ltd.目前擁有 1500525 股該公司的股票，價值 101435000 美元，此前在上個季度又購買了 854551 股。最後，Price T Rowe Associates Inc. MD 在第一季度將其在 Soleno Therapeutics 的持股增加了 47.2%。Price T Rowe Associates Inc. MD 目前擁有 2400418 股該公司的股票，價值 171510000 美元，此前在上個季度又購買了 769700 股。97.42% 的股票目前由機構投資者和對沖基金持有。</p>
</div><h2>About Soleno Therapeutics</h2>
<div class="lb-trans"><h2>關於 Soleno Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.</p>
<div class="lb-trans"><p>Soleno Therapeutics, Inc.是一家臨牀階段的生物製藥公司，專注於開發和商業化用於治療罕見疾病的新型療法。其主要候選藥物是氟氯噻噸氯化物緩釋片，這是一種每日一次的口服藥物，目前正在進行治療普拉德 - 威利綜合症的第三階段臨牀試驗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Soleno Therapeutics</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Top 3 Winter Stocks With Solid Growth Opportunities</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>2026 Comeback Picks: 3 S&amp;P Laggards Poised to Break Out</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Soleno Therapeutics 更好</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>三隻冬季股票具有良好的增長機會</li>
<li>三隻國防股票將受益於軍事支出增加</li>
<li>2026 年反彈股票：三隻標普滯後股有望突破</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>特斯拉多頭看到 500 美元的前景——但空頭警告痛苦的反轉</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Soleno Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Soleno Therapeutics 嗎？</h2>
</div><p>Before you consider Soleno Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Soleno Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Soleno Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Soleno Therapeutics 並不在名單上。</p>
</div><p>While Soleno Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Soleno Therapeutics 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Soleno 治療（NASDAQ:SLNO）股票跳空高開 - 接下來會發生什麼？